VolitionRx Limited (NYSE:VNRX) (“Volition”), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader (“KOL”) roundtable on sepsis management.
Remi Rabeuf, Lifecycle Leader at Volition, said: “We were delighted to bring together some of the world’s leading experts in sepsis to explore the potential of using Volition’s Nu.Q® NETs technology effectively in clinical practice. The panel discussed how Nu.Q® NETs could be used to enhance the management and outcome of sepsis patients and its potential application in early diagnosis, treatment guidance, treatment monitoring, and personalized medicine. The KOLs also discussed areas for future research.”
The roundtable was chaired by Professor Djillali Annane, Professor of Medicine at University Paris Saclay-UVSQ and University Versailles SQY, and comprised:
- Professor Evangelos J. Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Greece and Chair of the European Sepsis Alliance.
- Professor Mervyn Singer, University College London, UK. Co-chair of the Sepsis-3 Definitions International Task Force; past-chair, International Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior Investigator.
- Professor Adrienne Randolph, Professor of Anaesthesia and Paediatrics at Harvard Medical School, Paediatric Critical Care Physician at Boston Children’s Hospital, U.S. and Chair of the International Sepsis Forum.
- Dr Tanya Novak, PhD Scientist at Boston Children’s Hospital and an instructor at Harvard Medical School, U.S.
- Professor Michael Bauer, Professor and Chair of the Department of Anaesthesiology and Intensive Care Medicine at Jena University Hospital, Germany.
- Professor Guillaume Monneret, Professor of Immunology at Hospices Civils de Lyon, France.
- Professor Lea Payen, Professor in Molecular Biology and Toxicology at the University of Lyon I and Hospices Civils de Lyon, France.
- Dr Andrew Aswani, Consultant in Intensive Care Medicine and Anaesthesia at Guy’s and St Thomas’ Hospital in London, UK and Co-founder and Chief Medical Officer of Santersus AG.
- Dr Andrew Retter, Consultant in Intensive Care Medicine at Guys and St Thomas’ Hospital in London, UK and a Medical Consultant to Volition.
Read the full KOL Meeting report ‘Sepsis: hope of a brighter future’ here.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s technology go to: www.volition.com.
